[go: up one dir, main page]

PT3352584T - Composições e métodos para a sintetização de arn capeados em 5¿ - Google Patents

Composições e métodos para a sintetização de arn capeados em 5¿

Info

Publication number
PT3352584T
PT3352584T PT168494235T PT16849423T PT3352584T PT 3352584 T PT3352584 T PT 3352584T PT 168494235 T PT168494235 T PT 168494235T PT 16849423 T PT16849423 T PT 16849423T PT 3352584 T PT3352584 T PT 3352584T
Authority
PT
Portugal
Prior art keywords
synthesizing
compositions
methods
capped rnas
rnas
Prior art date
Application number
PT168494235T
Other languages
English (en)
Original Assignee
Trilink Biotechnologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58387109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3352584(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trilink Biotechnologies Llc filed Critical Trilink Biotechnologies Llc
Publication of PT3352584T publication Critical patent/PT3352584T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT168494235T 2015-09-21 2016-09-20 Composições e métodos para a sintetização de arn capeados em 5¿ PT3352584T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562221248P 2015-09-21 2015-09-21

Publications (1)

Publication Number Publication Date
PT3352584T true PT3352584T (pt) 2021-07-13

Family

ID=58387109

Family Applications (5)

Application Number Title Priority Date Filing Date
PT211731427T PT3954225T (pt) 2015-09-21 2016-09-20 Iniciadores de oligonucleótidos de iniciação para a sintetização de arn capeados em 5'
PT221904261T PT4140491T (pt) 2015-09-21 2016-09-20 Métolo para a sintetização de arn capeados em 5
PT168494235T PT3352584T (pt) 2015-09-21 2016-09-20 Composições e métodos para a sintetização de arn capeados em 5¿
PT211732789T PT3906789T (pt) 2015-09-21 2016-09-20 Iniciadores de oligonucleótidos de iniciação para a sintetização de arn capeados em 5'
PT221753775T PT4104687T (pt) 2015-09-21 2016-09-20 Composições e métodos para a sintetização de arn capeados em 5'

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT211731427T PT3954225T (pt) 2015-09-21 2016-09-20 Iniciadores de oligonucleótidos de iniciação para a sintetização de arn capeados em 5'
PT221904261T PT4140491T (pt) 2015-09-21 2016-09-20 Métolo para a sintetização de arn capeados em 5

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT211732789T PT3906789T (pt) 2015-09-21 2016-09-20 Iniciadores de oligonucleótidos de iniciação para a sintetização de arn capeados em 5'
PT221753775T PT4104687T (pt) 2015-09-21 2016-09-20 Composições e métodos para a sintetização de arn capeados em 5'

Country Status (21)

Country Link
US (9) US10913768B2 (pt)
EP (8) EP4140491B1 (pt)
JP (4) JP6814997B2 (pt)
KR (3) KR20240095306A (pt)
CN (8) CN116751827B (pt)
AU (5) AU2016328645C1 (pt)
CA (2) CA3218662A1 (pt)
CY (1) CY1124306T1 (pt)
DK (5) DK4140491T5 (pt)
ES (5) ES2879686T3 (pt)
FI (4) FI3954225T3 (pt)
HK (1) HK1255236A1 (pt)
HR (1) HRP20211091T1 (pt)
HU (5) HUE065704T2 (pt)
LT (5) LT4104687T (pt)
PL (5) PL3906789T3 (pt)
PT (5) PT3954225T (pt)
RS (1) RS62129B1 (pt)
SI (5) SI4140491T1 (pt)
SM (1) SMT202100396T1 (pt)
WO (1) WO2017053297A1 (pt)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
HUE065704T2 (hu) 2015-09-21 2024-06-28 Trilink Biotechnologies Llc Készítmények és módszerek 5-sapkával ellátott RNS-ek szintetizálására
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
EP4163374A1 (en) 2015-11-23 2023-04-12 The Regents of the University of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
WO2018075827A1 (en) 2016-10-19 2018-04-26 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
JP2020508056A (ja) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ 遺伝子編集のための組成物および方法
WO2018172556A1 (en) 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
AU2018265022A1 (en) 2017-05-10 2019-11-21 The Regents Of The University Of California Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9
RU2020103727A (ru) 2017-06-30 2021-07-30 Кодексис, Инк. Варианты рнк-полимеразы т7
AU2018292105B2 (en) * 2017-06-30 2024-12-12 Codexis, Inc. T7 RNA polymerase variants
AU2018298422B2 (en) 2017-07-04 2023-04-06 CureVac SE Novel nucleic acid molecules
EP4397757A3 (en) 2017-08-18 2024-10-23 ModernaTX, Inc. Rna polymerase variants
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
EA202090873A1 (ru) 2017-09-29 2020-08-17 Интеллиа Терапьютикс, Инк. Полинуклеотиды, композиции и способы редактирования генома
CN118530993A (zh) 2017-09-29 2024-08-23 因特利亚治疗公司 用于ttr基因编辑及治疗attr淀粉样变性的组合物及方法
CA3093509A1 (en) * 2018-03-15 2019-09-19 Biontech Rna Pharmaceuticals Gmbh 5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
US20210361761A1 (en) 2018-04-05 2021-11-25 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
BR112020020933A2 (pt) 2018-04-17 2021-04-06 Curevac Ag Moléculas de rna de rsv inovadoras e composições para vacinação
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
JP7352581B2 (ja) 2018-06-28 2023-09-28 キュアバック アールエヌエイ プリンター ゲーエムベーハー Ｒｎａインビトロ転写用バイオリアクター
US11685906B2 (en) 2018-12-06 2023-06-27 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
US20220040281A1 (en) 2018-12-21 2022-02-10 Curevac Ag Rna for malaria vaccines
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
EP3920950A1 (en) 2019-02-08 2021-12-15 CureVac AG Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
ES2980841T3 (es) 2019-02-11 2024-10-03 Ethris Gmbh Purificación de ARNm por filtración de flujo tangencial
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
EP3946598A1 (en) 2019-03-28 2022-02-09 Intellia Therapeutics, Inc. Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
EP3946285A1 (en) 2019-03-28 2022-02-09 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof
WO2020198641A2 (en) 2019-03-28 2020-10-01 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for polypeptide expression
WO2020214806A1 (en) * 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control
CA3138011A1 (en) * 2019-04-26 2020-10-29 Etherna Immunotherapies Nv Mrna formulation
US20220220189A1 (en) * 2019-05-24 2022-07-14 Ultragenyx Pharmaceutical Inc. Compositions and methods for treatment of hemochromatosis
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
WO2021020979A1 (en) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
CA3144902A1 (en) 2019-08-14 2022-01-19 Andreas Thess Rna combinations and compositions with decreased immunostimulatory properties
WO2021038089A1 (en) * 2019-08-29 2021-03-04 Universität Zürich Minimal messenger rnas and uses thereof
EP4076647A1 (en) 2019-12-20 2022-10-26 CureVac AG Lipid nanoparticles for delivery of nucleic acids
EP3886897A1 (en) 2020-02-04 2021-10-06 CureVac AG Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
PL432884A1 (pl) * 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
PL248416B1 (pl) * 2020-02-12 2025-12-08 Uniwersytet Warszawski Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
EP4112630B1 (en) * 2020-02-28 2024-10-16 Japan Science and Technology Agency Method for producing capped rna
CN113151312B (zh) * 2020-03-02 2022-12-09 中国科学院微生物研究所 新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用
CA3169889A1 (en) 2020-03-03 2021-09-10 Arcturus Therapeutics, Inc. Compositions and methods for the treatment of ornithine transcarbamylase deficiency
US11759515B2 (en) 2020-03-09 2023-09-19 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
IL296781A (en) 2020-03-30 2022-11-01 BioNTech SE Rna compositions targeting claudin-18.2
CN115768437A (zh) * 2020-04-21 2023-03-07 磨石生物公司 加帽化合物、组合物及其使用方法
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
WO2021222801A2 (en) 2020-05-01 2021-11-04 Arcturus Therapeutics, Inc. Nucleic acids and methods of treatment for cystic fibrosis
WO2021232099A1 (en) 2020-05-19 2021-11-25 Hudson Institute of Medical Research Oligonucleotides
JP2023530229A (ja) 2020-05-29 2023-07-14 キュアバック エスイー 核酸ベースの混合ワクチン
US12385039B2 (en) 2020-07-02 2025-08-12 Life Technologies Corporation Trinucleotide cap analogs, preparation and uses thereof
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2022036170A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN113234780A (zh) * 2020-08-20 2021-08-10 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
EP4157344A2 (en) 2020-08-31 2023-04-05 CureVac SE Multivalent nucleic acid based coronavirus vaccines
WO2022049093A1 (en) 2020-09-01 2022-03-10 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
CN116368226A (zh) * 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
CA3198727A1 (en) * 2020-10-20 2022-04-28 St Pharm Co., Ltd. Oligonucleotide for 5'-capped rna synthesis
CA3193238A1 (en) 2020-11-27 2022-06-02 Benyamin YAZDAN PANAH A device for preparing a dna product by means of capillary polymerase chain reaction
MX2023006126A (es) 2020-12-09 2023-07-28 BioNTech SE Produccion de arn.
WO2022125968A1 (en) 2020-12-11 2022-06-16 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing involving deamination
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US20240316090A1 (en) 2020-12-28 2024-09-26 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US20240122865A1 (en) 2021-02-19 2024-04-18 Pfizer Inc. Methods of Protecting RNA
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20250345524A1 (en) 2021-03-31 2025-11-13 CureVac SE Syringes containing pharmaceutical compositions comprising rna
KR20220140140A (ko) 2021-04-09 2022-10-18 한미정밀화학주식회사 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
IL308196A (en) 2021-05-04 2024-01-01 BioNTech SE Technologies for the early detection of interesting variants
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
MX2023015213A (es) 2021-06-22 2024-03-19 Intellia Therapeutics Inc Metodos para la edicion in vivo de un gen hepatico.
CN117858885A (zh) 2021-07-05 2024-04-09 国立研究开发法人科学技术振兴机构 核苷酸类的纯化方法和核苷酸类的纯化装置以及疏水性试剂和疏水性底物
EP4116313A1 (en) 2021-07-07 2023-01-11 Westfälische Wilhelms-Universität Münster Cap analog for the 5'-end of eukaryotic messenger rnas
MX2024001243A (es) 2021-07-29 2024-02-13 BioNTech SE Composiciones y metodos para el tratamiento de melanoma.
US20240342206A1 (en) 2021-07-30 2024-10-17 CureVac SE mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
EP4377326A1 (en) 2021-07-30 2024-06-05 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
JP2024534120A (ja) 2021-08-24 2024-09-18 ビオンテック・ソシエタス・エウロパエア インビトロ転写技術
CN113603739B (zh) 2021-08-27 2024-08-23 上海兆维科技发展有限公司 一种加帽类似物及其应用
US20250011826A1 (en) 2021-08-31 2025-01-09 Hanmi Fine Chemical Co., Ltd. mRNA CAP ANALOGUE AND USE THEREOF
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
CN113957108B (zh) * 2021-09-09 2025-01-10 上海兆维科技发展有限公司 一种加帽rna的合成方法以及加帽rna转录反应液
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4401838A1 (en) 2021-10-22 2024-07-24 BioNTech SE Oligosaccharide compounds and complexes
JP2024540979A (ja) 2021-10-22 2024-11-06 ビオンテック・ソシエタス・エウロパエア オリゴ糖複合体及び用途
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
JP2024540977A (ja) 2021-10-22 2024-11-06 ビオンテック・ソシエタス・エウロパエア ジスルフィドオリゴ糖化合物及び複合体
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
US20250057960A1 (en) 2021-10-22 2025-02-20 BioNTech SE Oligosaccharide complexes and uses
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
WO2023067126A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023081689A2 (en) 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20230083197A (ko) 2021-12-01 2023-06-09 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드
WO2023115495A1 (zh) * 2021-12-23 2023-06-29 北京毅新博创生物科技有限公司 质谱法检测mRNA加帽效率的方法
JP2025504908A (ja) 2022-01-28 2025-02-19 アイオバンス バイオセラピューティクス，インコーポレイテッド サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
KR20230123318A (ko) 2022-02-16 2023-08-23 에스티팜 주식회사 5'-캡핑된 rna 합성용 올리고뉴클레오티드
GB2615784A (en) 2022-02-18 2023-08-23 Phion Therapeutics Ltd mRNA vaccine
CN115260264B (zh) 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
AU2022430003B9 (en) 2022-02-28 2023-11-23 Guangzhou Henovcom Bioscience Co., Ltd. Compounds for rna capping and uses thereof
EP4486890A1 (en) 2022-03-01 2025-01-08 CRISPR Therapeutics AG Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023167880A2 (en) * 2022-03-01 2023-09-07 Verve Therapeutics, Inc. Compositions and methods for capping rnas
AU2023240501A1 (en) 2022-03-21 2024-10-31 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
EP4506353A4 (en) 2022-03-31 2025-07-09 Hanmi Fine Chemical Co Ltd MRNA CAP ANALOGUE AND ITS USES
CN114685588B (zh) * 2022-05-05 2024-03-29 江苏申基生物科技有限公司 一种含开环核苷结构的起始加帽寡核苷酸引物
GB2618818A (en) 2022-05-18 2023-11-22 Phion Therapeutics Ltd Vaccine
EP4531902A1 (en) 2022-05-25 2025-04-09 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US20250375534A1 (en) 2022-05-30 2025-12-11 BioNTech SE Complexes for delivery of nucleic acids
US20250215043A1 (en) * 2022-05-31 2025-07-03 Nutcracker Therapeutics, Inc. Rna cap analogs and methods of use
WO2023235422A2 (en) * 2022-05-31 2023-12-07 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
KR20250039517A (ko) 2022-06-16 2025-03-20 인텔리아 테라퓨틱스, 인크. 세포를 유전자 변형시키기 위한 방법 및 조성물
WO2023246860A1 (zh) * 2022-06-22 2023-12-28 江苏申基生物科技有限公司 一种起始加帽寡核苷酸引物及其制备方法和应用
CN114853836B (zh) * 2022-06-24 2024-05-14 江苏申基生物科技有限公司 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用
CN115057903B (zh) * 2022-06-22 2024-03-29 江苏申基生物科技有限公司 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用
CN115109110B (zh) * 2022-06-22 2024-07-12 江苏申基生物科技有限公司 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN114941018B (zh) * 2022-06-28 2023-09-22 翌圣生物科技(上海)股份有限公司 cap1帽类似物的合成方法
KR20240010238A (ko) 2022-07-15 2024-01-23 한미정밀화학주식회사 캡 유사체 및 이의 용도
US11898186B1 (en) 2022-08-10 2024-02-13 Genscript Usa Inc. Compositions and methods for preparing capped mRNA
CN115925773A (zh) * 2022-08-23 2023-04-07 合肥华纳生物医药科技有限公司 一种新型信使核糖核酸帽类似物
WO2024044741A2 (en) * 2022-08-26 2024-02-29 Trilink Biotechnologies, Llc Efficient method for making highly purified 5'-capped oligonucleotides
CN117645642A (zh) * 2022-09-05 2024-03-05 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
JP2025531877A (ja) 2022-09-09 2025-09-25 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
CA3267272A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa FLU VIRUS VACCINES
CN120583964A (zh) 2022-09-26 2025-09-02 生物技术欧洲股份公司 核酸复合物及其用途
WO2024075022A2 (en) 2022-10-04 2024-04-11 BioNTech SE Rna constructs and uses thereof
EP4598954A1 (en) 2022-10-06 2025-08-13 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
EP4605010A1 (en) 2022-10-21 2025-08-27 BioNTech SE Nucleic acid complexes and uses thereof
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
CN116143855B (zh) * 2022-11-08 2023-11-28 江苏申基生物科技有限公司 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用
EP4638736A1 (en) 2022-12-23 2025-10-29 Intellia Therapeutics, Inc. Systems and methods for genomic editing
EP4397669A1 (en) 2023-01-06 2024-07-10 Westfälische Wilhelms-Universität Münster Photocaged cap analogs for the 5'-end of rnas
EP4651891A1 (en) 2023-01-20 2025-11-26 Astrazeneca AB Nucleic acid molecules
IL322193A (en) 2023-01-20 2025-09-01 Astrazeneca Ab Vaccination
WO2024160895A1 (en) 2023-01-31 2024-08-08 CureVac SE Cap analogs with 5'-terminal acyclic guanosine derivative
EP4658239A1 (en) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
CN120813591A (zh) 2023-03-03 2025-10-17 株式会社纳蒂亚斯 多磷酸化核苷、用于其合成的磷酸部分活化核苷酸及其合成方法、以及使用磷酸部分活化核苷酸的多磷酸化核苷的合成方法
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
TW202444906A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 用於靶向pcsk9之組合物及方法
WO2024206565A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Repressor fusion protein systems
CN118726510A (zh) * 2023-03-31 2024-10-01 苏州近岸蛋白质科技股份有限公司 一管法酶促合成加帽mRNA的方法
CN118772219B (zh) * 2023-04-04 2025-12-02 深圳瑞吉生物科技有限公司 一种用于核酸的5’端加帽的含卤化合物及其应用
CN121001738A (zh) 2023-04-27 2025-11-21 葛兰素史克生物有限公司 流感病毒疫苗
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024235451A1 (en) 2023-05-16 2024-11-21 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
WO2024245907A1 (en) 2023-05-26 2024-12-05 CureVac SE Cancer antigens
WO2024260570A1 (en) 2023-06-23 2024-12-26 CureVac SE Nucleic acid encoded antibodies
WO2025022290A1 (en) 2023-07-21 2025-01-30 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
WO2025027060A1 (en) 2023-07-31 2025-02-06 CureVac SE Nucleic acid encoded runx3 transcription factor
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025027089A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thiolipids and uses thereof
WO2025036992A1 (en) 2023-08-16 2025-02-20 CureVac SE Rna conjugates
WO2025054401A2 (en) * 2023-09-06 2025-03-13 Trilink Biotechnologies, Llc Cap analogs and methods of use thereof
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025071359A1 (ko) 2023-09-27 2025-04-03 한미정밀화학 주식회사 mRNA 캡 유사체 및 이의 용도
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2025101994A2 (en) 2023-11-10 2025-05-15 Intellia Therapeutics, Inc. Compositions, methods, and systems for genomic editing
WO2025103803A1 (en) 2023-11-13 2025-05-22 CureVac SE Immunotherapy against neuronal and brain tumors
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025129157A1 (en) 2023-12-15 2025-06-19 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of canavan disease
WO2025137301A1 (en) 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Methods for rapid engineering of cells
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025134062A2 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025147660A2 (en) 2024-01-04 2025-07-10 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
US20250269059A1 (en) 2024-02-27 2025-08-28 Crispr Therapeutics Ag Rt editing compositions and methods
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
US12492420B2 (en) 2024-03-29 2025-12-09 New England Biolabs, Inc. Compositions, kits, and methods for in vitro transcription
EP4650358A2 (en) * 2024-04-26 2025-11-19 Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. Ribose-modified cap analog and use thereof
WO2025240940A1 (en) 2024-05-17 2025-11-20 Scribe Therapeutics Inc. Compositions and methods for the targeting of apolipoprotein c3
WO2025242815A1 (en) 2024-05-23 2025-11-27 CureVac SE Immunotherapy of squamous cell carcinoma
CN120608113A (zh) * 2024-11-29 2025-09-09 上海蓝鹊生物医药有限公司 一种合成Cap2结构5'-加帽RNA的组合和方法
CN119306779A (zh) * 2024-12-13 2025-01-14 上海科泽永欣生物科技有限公司 一种含r构型的起始加帽寡核苷酸引物及其合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1997A (en) 1841-03-03 Improvement in the mode of rendering fabrics water-proof
EP0081099A3 (en) * 1981-12-04 1983-08-10 Sloan-Kettering Institute For Cancer Research Capped oligonucleotide anti-viral agents
DE3148702C2 (de) * 1981-12-09 1985-05-15 Dieter Gräßlin Feinwerktechnik, 7742 St Georgen Programmierbare Steuereinrichtung, insbesondere für schaltende Zeitmeßgeräte
US5837852A (en) 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
AU2998800A (en) 1999-03-24 2000-10-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The N-acylphosphoramidites and their use in oligonucleotide synthesis
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7629325B2 (en) * 2004-10-11 2009-12-08 Technion Research & Development Foundation Ltd. Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy
CA2589406A1 (en) 2004-12-09 2006-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
DE602007013223D1 (de) 2006-06-01 2011-04-28 Trilink Biotechnologies San Diego Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
US8304529B2 (en) 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
US20080248469A1 (en) 2006-08-16 2008-10-09 Applera Corporation Methods for Identifying Nucleotides of Interest in Target Polynucleotides
CN104072561B (zh) 2007-06-19 2017-12-22 路易斯安那州州立大学及农业机械学院管理委员会 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US9067964B2 (en) 2008-12-18 2015-06-30 Oligomer Sciences Ab Complex and method for enhancing nuclear delivery
US8557972B2 (en) 2009-12-21 2013-10-15 University Of Washington Through Its Center For Commercialization Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA
WO2011157617A1 (en) 2010-06-17 2011-12-22 Febit Holding Gmbh Complex set of mirna libraries
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
AU2013243952A1 (en) * 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL3495505T3 (pl) 2013-03-14 2025-01-13 Translate Bio, Inc. Ocena ilościowa wydajności czapeczki informacyjnego rna
JP6148592B2 (ja) 2013-10-15 2017-06-14 ヤマハ発動機株式会社 車速決定システム、安定制御システム及びそれを備えた鞍乗り型車両
EP3233880A1 (en) 2014-12-16 2017-10-25 Novartis AG End capped nucleic acid molecules
HUE065704T2 (hu) 2015-09-21 2024-06-28 Trilink Biotechnologies Llc Készítmények és módszerek 5-sapkával ellátott RNS-ek szintetizálására
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
WO2018075827A1 (en) 2016-10-19 2018-04-26 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
CA3093509A1 (en) 2018-03-15 2019-09-19 Biontech Rna Pharmaceuticals Gmbh 5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
PL248416B1 (pl) 2020-02-12 2025-12-08 Uniwersytet Warszawski Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
PL432884A1 (pl) 2020-02-12 2021-08-16 Uniwersytet Warszawski Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
WO2021213924A1 (en) 2020-04-22 2021-10-28 BioNTech SE Coronavirus vaccine
US12385039B2 (en) 2020-07-02 2025-08-12 Life Technologies Corporation Trinucleotide cap analogs, preparation and uses thereof
CA3198727A1 (en) 2020-10-20 2022-04-28 St Pharm Co., Ltd. Oligonucleotide for 5'-capped rna synthesis

Also Published As

Publication number Publication date
AU2021206780C1 (en) 2024-01-04
US20240158433A1 (en) 2024-05-16
US20210261597A1 (en) 2021-08-26
LT4104687T (lt) 2024-02-26
EP4276189A2 (en) 2023-11-15
SI4140491T1 (sl) 2024-01-31
EP4424835A3 (en) 2024-10-23
US20190270766A1 (en) 2019-09-05
EP3906789A1 (en) 2021-11-10
HK1255236A1 (zh) 2019-08-09
SI3906789T1 (sl) 2024-03-29
DK4140491T5 (da) 2024-07-22
US20190144490A1 (en) 2019-05-16
EP4424835A2 (en) 2024-09-04
KR20240095306A (ko) 2024-06-25
DK3954225T5 (da) 2024-08-05
EP3954225B1 (en) 2023-11-22
HUE064227T2 (hu) 2024-02-28
EP4104687A1 (en) 2022-12-21
CN121085982A (zh) 2025-12-09
PL3352584T3 (pl) 2021-11-08
CN113584020A (zh) 2021-11-02
EP4104687B1 (en) 2024-01-31
SI3954225T1 (sl) 2024-03-29
PT3954225T (pt) 2024-01-02
DK4104687T5 (da) 2024-07-22
KR102500198B1 (ko) 2023-02-16
ES2968335T3 (es) 2024-05-09
FI4104687T3 (fi) 2024-03-01
CY1124306T1 (el) 2022-07-22
LT3906789T (lt) 2024-02-12
JP6814997B2 (ja) 2021-01-20
AU2023229522A1 (en) 2023-09-28
AU2016328645B2 (en) 2021-05-13
AU2021206780B2 (en) 2023-04-06
AU2023201915B2 (en) 2024-07-25
HUE065704T2 (hu) 2024-06-28
US11414453B2 (en) 2022-08-16
DK3352584T3 (da) 2021-07-12
KR20230026535A (ko) 2023-02-24
CN116751827B (zh) 2024-01-30
AU2016328645C1 (en) 2021-10-28
KR102670937B1 (ko) 2024-05-31
JP2024150459A (ja) 2024-10-23
HRP20211091T1 (hr) 2021-10-15
CN120842296A (zh) 2025-10-28
US12103944B2 (en) 2024-10-01
CN116751827A (zh) 2023-09-15
EP3954224A1 (en) 2022-02-16
JP2021048864A (ja) 2021-04-01
US12258369B2 (en) 2025-03-25
US11578095B2 (en) 2023-02-14
PT4140491T (pt) 2023-12-05
SMT202100396T1 (it) 2021-09-14
SI4104687T1 (sl) 2024-03-29
US20210371452A1 (en) 2021-12-02
LT3954225T (lt) 2024-02-12
US10494399B2 (en) 2019-12-03
PL3906789T3 (pl) 2024-05-20
AU2021206780A1 (en) 2021-08-12
CN116590285A (zh) 2023-08-15
CA3218662A1 (en) 2017-03-30
US20240140982A1 (en) 2024-05-02
JP2022109973A (ja) 2022-07-28
CN117025590A (zh) 2023-11-10
PT3906789T (pt) 2023-12-18
US10519189B2 (en) 2019-12-31
JP7594563B2 (ja) 2024-12-04
WO2017053297A1 (en) 2017-03-30
CA2999274A1 (en) 2017-03-30
US20220289786A1 (en) 2022-09-15
PL4104687T3 (pl) 2024-05-27
LT3352584T (lt) 2021-08-10
JP2018527015A (ja) 2018-09-20
PT4104687T (pt) 2024-02-27
EP3352584A1 (en) 2018-08-01
ES2968391T3 (es) 2024-05-09
HUE055458T2 (hu) 2021-11-29
FI4140491T3 (fi) 2023-11-20
AU2023201915A1 (en) 2023-05-04
DK4140491T3 (da) 2023-11-27
ES2972098T3 (es) 2024-06-11
RS62129B1 (sr) 2021-08-31
AU2023229522B2 (en) 2025-02-20
ES2964690T3 (es) 2024-04-09
LT4140491T (lt) 2023-11-10
ES2879686T3 (es) 2021-11-22
CA2999274C (en) 2023-12-19
PL4140491T3 (pl) 2024-02-26
EP4276189A3 (en) 2024-01-17
DK3954225T3 (da) 2024-01-02
US20250171489A1 (en) 2025-05-29
EP4140491A1 (en) 2023-03-01
EP4140491B1 (en) 2023-09-13
HUE065203T2 (hu) 2024-05-28
HUE065331T2 (hu) 2024-05-28
CN108366604A (zh) 2018-08-03
KR20180050409A (ko) 2018-05-14
US10913768B2 (en) 2021-02-09
SI3352584T1 (sl) 2021-09-30
CN121064267A (zh) 2025-12-05
AU2016328645A1 (en) 2018-04-19
DK3906789T5 (da) 2024-08-05
JP7082174B2 (ja) 2022-06-07
FI3954225T3 (fi) 2023-12-28
US11878991B2 (en) 2024-01-23
EP3906789B1 (en) 2023-11-22
FI3906789T3 (fi) 2024-01-11
PL3954225T3 (pl) 2024-05-20
US20180273576A1 (en) 2018-09-27
EP3352584B1 (en) 2021-05-12
DK3906789T3 (da) 2024-01-08
EP3954225A1 (en) 2022-02-16
EP3352584A4 (en) 2019-03-27
DK4104687T3 (da) 2024-03-04
AU2025203425A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
SI3352584T1 (sl) Sestavki in postopki za sintezo 5'-omejenih RNAjev
IL287789A (en) Mogroside compounds, methods for their preparation, preparations including them and their uses
IL273817A (en) Preparations and methods for editing rna
IL259576A (en) Preparations and methods for immuno-oncology
SI3580561T1 (sl) Metode, osnovane na hla, in njihove sestave ter uporabe
IL286391A (en) Penfluramine preparations and methods for their preparation
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
IL271680A (en) Compositions and methods for inhibiting expression of HMGB1
IL274524A (en) Preparations and methods for aquaculture
SG11201803284YA (en) Novel method of use and compositions
GB201512996D0 (en) Compositions and methods
GB201514413D0 (en) Compositions and methods
GB201521083D0 (en) Compositions for treatment and methods thereof